Skip to content Skip to footer
Subscribe Now

NEWS

NexEos Bio Receives US FDA IND Clearance to Advance NTX-1024 into P-II/III Study for Vernal Keratoconjunctivitis
Shots: The US FDA has cleared NexEos Bio’s IND application to initiate a P-II/III clinical study of NTX-1024 ophthalmic solution for the treatment of vernal keratoconjunctivitis (VKC) The P-II/III study will evaluate the safety and efficacy of NTX-1024 in VKC, following positive results from an open-label investigator-initiated study showing improvements in symptoms and ocular inflammation…
February 20, 2026
Novartis
Novartis AG to Transfer Stake in Novartis India Limited to ChrysCapital
Shots: Novartis AG has signed an agreement with ChrysCapital to divest its 70.68% stake in Novartis India Limited (NIL), following a strategic review initiated in Feb 2024 The transaction, subject to customary closing conditions, is expected to close in Q3’26; the Board of NIL was formally notified post-signing Post-divestment, Novartis will further its transition into…
February 20, 2026
Hims & Hers to Acquire Eucalyptus for ~$1.15B
Shots: Hims & Hers has entered into a definitive agreement to acquire Eucalyptus, to expand into Australia and Japan, and deepen its presence in the UK, Germany, and Canada As per the deal, Hims & Hers will acquire Eucalyptus for up to ~$1.15B, including upfront ~$240M in cash The acquisition is expected to close mid-2026,…
February 20, 2026
Covetrus to Merge with Cencora’s MWI Animal Health in a $3.5B Deal
Shots: Cencora & Covetrus have entered into a definitive agreement to merge Covetrus with MWI Animal Health, forming a unified company delivering a comprehensive animal health platform The deal values MWI at a $3.5B enterprise value, with Cencora receiving $1.25B in cash, $800M in preferred equity, & $1.45B in common equity, securing a 34.3% non-controlling…
February 19, 2026
Zydus Lifesciences  Launches Anyra (Biosimilar, Eylea) in the Canada 
Shots:  Zydus Lifesciences has launched Anyra (aflibercept 2 mg), a biosimilar version of Eylea. Zydus has inked an agreement with Regeneron and Bayer  Aflibercept is a Vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PlGF), which are members of the VEGF family of angiogenic factors that can act as mitogenic, chemotactic, and vascular permeability…
February 19, 2026
Eli lilly
Eli Lilly Reports the P-IIIb (TOGETHER-PsO) Trial Data on Taltz + Zepbound for Adults with Psoriasis and Obesity or Overweight
Shots: Eli Lilly has reported P-IIIb (TOGETHER-PsO) trial data assessing Taltz (ixekizumab) + Zepbound (tirzepatide) vs Taltz alone in 274 adults with mod. to sev. plaque psoriasis & obesity/overweight with ≥1 additional weight-related comorbid condition At 36wks., the trial met its 1EP with 27.1% pts reaching PASI 100 & ≥10% weight loss compared to 5.8% pts. Trial…
February 19, 2026
Load more